Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06826859 · ClinicalTrials.gov registry record · Phase 1
Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)
A Phase 1 study of Preeclampsia and Preterm Birth, sponsored by Thomas Jefferson University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT06826859: Recruiting Phase 1 study of Preeclampsia and Preterm Birth, sponsored by Thomas Jefferson University.
NCT06826859 is a Phase 1 study of Preeclampsia and Preterm Birth that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 400 participants, below the 1,118-participant average among 48 other Preeclampsia trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06826859, a Phase 1 study of Preeclampsia and Preterm Birth, is actively recruiting participants, sponsored by Thomas Jefferson University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
Aspirin is recommended in high risk patients to reduce the risk of preeclampsia and preterm birth, which are leading causes of both maternal and neonatal morbidity and mortality, but up to 20% will have these adverse outcomes despite therapy. Gaps in knowledge regarding pregnancy specific aspirin pharmacology and the relationship of aspirin response and pregnancy outcome, along with a lack of consensus on aspirin dosing has limited the effective use of this intervention. The investigators aim to apply principles of clinical pharmacology to determine how to optimally utilize this low cost medication to improve maternal/child health outcomes. This is a Phase I/II randomized controlled trial of high risk pregnancies recommended aspirin; participants will be randomized to take aspirin either 162mg once daily, or 81mg twice a day. Outcomes evaluated will include the difference in aspirin response between these two dosing regimens, the individual factors that impact aspirin pharmacology in pregnancy, and evaluate markers or aspirin response that may be associated with pregnancy outcome.
Primary Outcome
Difference in PFA-100 epinephrine closure time (seconds)
Conditions Studied
Interventions
- DRUG Daily aspirin (ASA)
- DRUG Split dose aspirin (ASA)
Study Locations (1)
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-06-26 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 1 |
What NCT06826859 shows while recruiting
NCT06826859 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 1,118-participant average among 48 other Preeclampsia trials with a reported enrollment target (64% lower).
The record links to 2 conditions, with Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which Daily aspirin (ASA) is the first listed.
NCT06826859 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06826859 about?
NCT06826859 is a clinical study titled "Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)". Aspirin is recommended in high risk patients to reduce the risk of preeclampsia and preterm birth, which are leading causes of both maternal and neonatal morbidity and mortality, but up to 20% will have these adverse outcomes despite therapy. Gaps in knowledge regarding pregnancy specific aspirin ph...
What is the current status of trial NCT06826859?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 400 participants. The study started on 2025-06-26. Estimated completion is 2029-12-31.
What conditions does trial NCT06826859 study?
This clinical trial studies the following conditions: Preeclampsia, Preterm Birth.
What interventions are being tested in trial NCT06826859?
The interventions under investigation include: Daily aspirin (ASA) (DRUG), Split dose aspirin (ASA) (DRUG).
Who is sponsoring clinical trial NCT06826859?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06826859 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06826859's enrollment target sits among peer trials
400 14th of 48 higher than 35 of 48 other Preeclampsia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Preeclampsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pravastatin for Prevention of Preeclampsia
COMPLETED · Phase 1
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy
RECRUITING · NA
-
Exosome Cargo From Preeclampsia Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI